Amgen sales rise, but shares off as investors await obesity data
By Deena Beasley (Reuters) -Amgen on Tuesday said third-quarter sales rose 5%, but a full-year sales forecast raise only reflected additional revenue from its $27.8 billion acquisition this month of Horizon Therapeutics and its shares fell nearly 4%. Sales of some high profile medicines also fell short of expectations, likely contributing to the share move….
